Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 10/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853086 | 1.00 | PREP (0.44) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL2790529 | 0.88 | PREP (0.47) | PREPPSMB5CXCR2F2 | |
| SCHEMBL2788790 | 0.87 | PREP (0.44) | PREPPSMB5CXCR2F2 | |
| SCHEMBL21911818 | 0.86 | PSMB5 (0.39) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL20571176 | 0.86 | PSMB5 (0.39) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL23200672 | 0.86 | PSMB5 (0.39) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL21955866 | 0.86 | PREP (0.38) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL20571080 | 0.85 | PREP (0.44) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL21911461 | 0.85 | PREP (0.44) | PREPPSMB5CXCR2F2PRSS1 | |
| SCHEMBL23200757 | 0.84 | PREP (0.44) | PREPPSMB5CXCR2F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
| EP-2970340-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151958-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | PREP 23/4885PSMB5 1315/4885CXCR2 3164/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | PREP 23/4885PSMB5 1315/4885CXCR2 3164/4885 |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PREP 209/4885PSMB5 1165/4885CXCR2 4511/4885 |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PREP 209/4885PSMB5 1165/4885CXCR2 4511/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | PREP 23/4885PSMB5 1315/4885CXCR2 3164/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PREP 209/4885PSMB5 1165/4885CXCR2 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.